Lynx1 Capital Management LP, 10% Owner at Cullinan Therapeutics, Inc. (CGEM), bought 265,934 shares at $7.94 ($2.2M) on 2025-10-15, disclosed to the SEC on 2025-10-21.
Open-market purchase of $2.2M CGEM by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.94 | 51,500 | $409K | 18.2% |
| 2 | $8.86 | 150,000 | $1.3M | 59.2% |
| 3 | $7.84 | 32,217 | $253K | 11.3% |
| 4 | $7.84 | 32,217 | $253K | 11.3% |
| Total | $8.43 avg | 265,934 | $2.2M | 100% |
| Filing → |
| KRRO | BUY | 2026-04-02 | $6K | — | Filing → |
| TCRX | BUY | 2025-12-23 | $218K | — | Filing → |
| NEUP | BUY | 2025-10-23 | $6.6M | — | Filing → |